Journal of Human Reproductive Science
Home Ahead of Print Current Issue Archives
   Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size    Users online: 1050


 
ORIGINAL ARTICLE Table of Contents   
Year : 2015  |  Volume : 8  |  Issue : 1  |  Page : 25-29
Different gonadotropin releasing hormone agonist doses for the final oocyte maturation in high-responder patients undergoing in vitro fertilization/intra-cytoplasmic sperm injection


1 Department of Obstetrics and Gynecology, Faculty of Medicine, Ufuk University, Turkey
2 Department of Obstetrics and Gynecology, Faculty of Medicine, Ufuk University; Centrum Clinic Women Healthcare and IVF Center, Ankara; Dogu Fertil IVF Center, Malatya, Turkey

Correspondence Address:
Emre Goksan Pabuccu
Nenehatun Street, No: 59, Gaziosmanpasa, Ankara
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0974-1208.153123

Rights and Permissions

Context: Efficacy of gonadotropin releasing hormone agonists (GnRH-a) for ovulation in high-responders. Aims: The aim of the current study is to compare the impact of different GnRH-a doses for the final oocyte maturation on cycle outcomes and ovarian hyperstimulation syndrome (OHSS) rates in high-responder patients undergoing ovarian stimulation. Settings And Designs: Electronic medical records of a private in vitro fertilization center, a retrospective analysis. Subjects and Methods: A total of 77 high-responder cases were detected receiving GnRH-a. Group I consisted of 38 patients who received 1 mg of agonist and Group II consisted of 39 patients who received 2 mg of agonist. Statistical Analysis: In order to compare groups, Student's t-test, Mann-Whitney U-test, Pearson's Chi-square test or Fisher's exact test were used where appropriate. A P < 0.05 was considered as statistically significant. Result: Number of retrieved oocytes (17.5 vs. 15.0, P = 0.510), implantation rates (46% vs. 55.1%, P = 0.419) and clinical pregnancy rates (42.1% vs. 38.5%, P = 0.744) were similar among groups. There were no mild or severe OHSS cases detected in Group I. Only 1 mild OHSS case was detected in Group II. Conclusion: A volume of 1 or 2 mg leuprolide acetate yields similar outcomes when used for the final oocyte maturation in high-responder patients.


[FULL TEXT] [PDF]*
Print this article  Email this article
    

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3192    
    Printed30    
    Emailed0    
    PDF Downloaded125    
    Comments [Add]    

Recommend this journal